Altimmune, Inc. (ALT)

Altimmune announced positive 48-week data from its IMPACT Phase 2b trial of pemvidutide in December 2025. The company was added to the Nasdaq Biotechnology Index (NBI) in December 2024. Altimmune announced a CEO transition and succession plan in December 2025. The company reported its Q3 2025 earnings, with a cash position of $211 million as of September 30. UBS initiated coverage of Altimmune with a "buy" rating and a price target of $26 in November 2024. Altimmune received FDA Breakthrough Therapy Designation for pemvidutide in MASH in January 2026. The company announced the pricing and closing of a $75 million registered direct equity offering in January 2026.

As a clinical-stage biopharmaceutical company, Altimmune's products are not yet commercialized, so traditional demand seasonality does not apply. The company's progress is driven by clinical trials, regulatory milestones, and financing activities, which do not follow seasonal patterns.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for metabolic and liver diseases, including obesity, MASH, AUD, and ALD. Its lead product candidate, pemvidutide, is in Phase 3 trials for obesity and MASH, and Phase 2 trials for AUD and ALD. Pemvidutide activates both GLP-1 and glucagon receptors, mimicking the effects of diet and exercise on weight loss and liver fat metabolism.

Altimmune, Inc. is headquartered in Gaithersburg, Maryland, United States. Its primary operations, including research, development, and clinical trials, are based in the U.S.

Altimmune's brand reputation appears positive, driven by clinical developments and analyst sentiment. The company has a consensus rating of "Moderate Buy" with an average target price suggesting upside potential. Strong clinical trial results for pemvidutide in MASH and its FDA Breakthrough Therapy Designation contribute to this positive perception.

Altimmune's stock ownership includes institutional, retail, and individual investors. As of Q4 2025, 396 institutions held shares, accounting for 40.57% of the total shares. Approximately 60.46% of Altimmune's stock is held by insiders. Retail investors hold approximately 77.20% of the company's stock.